MARKET

ITCI

ITCI

Intra-Cellular Therapies
NASDAQ
126.20
-0.06
-0.05%
After Hours: 126.18 -0.02 -0.02% 17:52 01/17 EST
OPEN
126.65
PREV CLOSE
126.26
HIGH
126.74
LOW
126.16
VOLUME
6.02M
TURNOVER
--
52 WEEK HIGH
128.00
52 WEEK LOW
62.78
MARKET CAP
13.38B
P/E (TTM)
-146.8296
1D
5D
1M
3M
1Y
5Y
1D
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Benzinga · 7h ago
Netflix, Procter & Gamble, Johnson & Johnson Report Results In Holiday-Shortened Week
Seeking Alpha · 1d ago
Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
TipRanks · 2d ago
Roth MKM biotech analyst holds an analyst/industry conference call
TipRanks · 3d ago
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks · 3d ago
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular
Barchart · 4d ago
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
NASDAQ · 5d ago
Intra-Cellular Therapies Cut to Neutral From Overweight by Piper Sandler
Dow Jones · 5d ago
More
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Webull offers Intra-Cellular Therapies Inc stock information, including NASDAQ: ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.